RxDoctor Payments Data

Jason Moshier, MD

Internal Medicine · Goshen, INNPI 1982672242

Payments from drug & device makers

$598in general payments, 2019–2025

Across 28 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$169
  • Pfizer$115
  • Boehringer Ingelheim$108
  • Lilly USA, LLC$92
  • Abbott$33
  • Boston Scientific$21
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$57997%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$598 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$199,207
Medicare patients
355
Services billed
2,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$211,664
JardianceEmpagliflozin140$123,233
EliquisApixaban84$90,191
MounjaroTirzepatide66$80,829
JanuviaSitagliptin Phosphate50$56,299
TrulicityDulaglutide51$52,033
FarxigaDapagliflozin Propanediol22$39,282
Breo ElliptaFluticasone/Vilanterol77$38,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,455
XareltoRivaroxaban29$30,698
Tresiba Flextouch U-100Insulin Degludec25$28,095
ProliaDenosumab15$25,925
MyrbetriqMirabegron39$23,813
AbrysvoRsv Vacc, Pref A And Pref B/Pf72$22,971
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$19,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$169$218,016168 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat$108$163,734178 claims
Lilly USA, LLCMounjaro, Trulicity$92$132,861117 claims
PfizerEliquis, Abrysvo$115$113,161156 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$15$58,74574 claims
AmgenProlia$15$25,92515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →